Cellectar Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLRB research report →
About the company
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.
- CEO
- James V. Caruso
- IPO
- 2005
- Employees
- 11
- HQ
- Florham Park, NJ, US
Price Chart
- Market Cap
- $8.97M
- P/E
- -0.38
- P/S
- 0.00
- P/B
- 2.53
- EV/EBITDA
- -0.10
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -264.79%
- ROIC
- -358.20%
- Revenue
- $0 · 0.00%
- Net Income
- $-21,791,037 · 51.12%
- EPS
- $-8.35 · 77.14%
- Op Income
- $-22,979,844
- FCF YoY
- 51.51%
- 52W High
- $6.52
- 52W Low
- $2.20
- 50D MA
- $2.79
- 200D MA
- $3.36
- Beta
- 0.55
- Avg Volume
- 1.05M
Get TickerSpark's AI analysis on CLRB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Gu Andrew | other | 0 |
| May 7, 26 | Longcor Jarrod | buy | 26,040 |
| May 7, 26 | Longcor Jarrod | buy | 8,680 |
| May 7, 26 | CARUSO JAMES V | buy | 26,040 |
| May 7, 26 | CARUSO JAMES V | buy | 8,680 |
| Dec 12, 25 | NEIS JOHN | sell | 198 |
| Jul 2, 25 | CARUSO JAMES V | buy | 10,000 |
| Jul 2, 25 | CARUSO JAMES V | buy | 10,000 |
| Jul 2, 25 | Longcor Jarrod | buy | 10,000 |
| Jul 2, 25 | Longcor Jarrod | buy | 10,000 |
Our CLRB coverage
Recent articles, reports, and earnings notes.
No research on CLRB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CLRB report →Similar companies
Peers in the same neighborhood.